SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin eyes revenue of over Rs 780 crore from oral contraceptives in US

28 Nov 2011 Evaluate

Lupin is expecting revenues of over Rs 780 crore (up to $150 million) from its oral contraceptive (OC) segment in the US market by 2013-14, a segment in which it had forayed recently. In September this year, the drug firm entered into OC segment in US after the US health regulator approved its generic norethindrone tablets in the strength of 0.35 mg.

The company has received two more approvals from the US Food and Drug Administration (USFDA) in the OC segment, since its foray taking the total approvals in the US market to three. Apart from generic norethindrone tablets, the company has received approvals from the USFDA to market generic versions of LoSeasonique tablets and Femcon Fe respectively.

Till date, the company's OC segment pipeline consists of 30 filings out of which it has already received approval for three generic drugs. The US market for oral contraceptives is pegged to be around $4.5 billion, according to industry estimates.

Further, according to IMS Health data, Lupin remains the fifth largest generic player in the US in terms of prescriptions and is currently the market leader in 14 out of 30 generic products in the US.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×